非小细胞肺癌小分子靶向药物耐药处理共识
中国抗癌协会肺癌专业委员会执笔:吴一龙1, 廖美琳2, 周清华3, 蒋国樑4, 陆舜2, 王洁5, 程颖6, 张力7, 张绪超1, 刘晓晴8,1, 韩宝惠2, 钟文昭1, 周彩存9, 宋勇10, 马胜林11, 王长利12, 杨学宁1, 毛伟敏13, 王俊14, 许林15, 陈海泉4, 傅小龙4, 冯继锋15, 宋启斌16, 于世英17, 伍钢18, 朱广迎5, 陈公琰19, 熊建萍20, 杨衿记1, 王建军18, 陈克能5, 申屠阳2, 张沂平13, 胡艳萍21, 于丁21, 宋恕平22, 胡成平23, 宋向群24, 常建华4, 陈刚1, 张贺龙25, 李伟雄1, 王震1

The Consensus of Non-Small Cell Lung Cancer with Small Molecular Targeted Drug Resistance
WU Yi-long1, LIAO Mei-lin2, ZHOU Qing-hua3, JIANG Guo-liang4, LU Shun2, WANG Jie5, CHENG Ying6, ZHANG Li7, ZHANG Xu-chao1, LIU Xiao-qing8, HAN Bao-hui2, ZHONG Wen-zhao1, ZHOU Cai-cun9, SONG Yong10, MA Sheng-lin11, WANG Chang-li12, YANG Xue-ning1, MAO Wei-min13, WANG Jun14, XU Lin15, CHEN Hai-quan4, FU Xiao-long4, FENG Ji-feng15, SONG Qi-bin16, YU Shi-ying17, WU Gang18, ZHU Guang-ying5, CHEN Gong-yan19, XIONG Jian-ping20, YANG Jin-ji1, WANG Jian-jun18, CHEN Ke-neng5, SHEN Tu-yang2, ZHANG Yi-ping13, HU Yan-ping21, YU Ding21, SONG Shu-ping22, HU Cheng-ping23, SONG Xiang-qun24, CHANG Jian-hua4, CHEN Gang1, ZHANG He-long25, LI Wei-xiong1, WANG Zhen1
图1 EGFR TKI耐药后的临床管理策略